Know Cancer

or
forgot password

National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)


N/A
18 Years
N/A
Not Enrolling
Both
Cancer, Solid Tumor

Thank you

Trial Information

National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)


Inclusion Criteria:



- Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week

- Patient examined AND with a routine blood test planned

- Patient informed of procedure for the study who was not opposed to it

Exclusion Criteria:

- Patient treated for malignant hemopathy

- Patient no treated by inhibitor of thyrosine kinase or for less than 1 week

- Patients with no routine blood laboratory tests planned

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

To evaluate the prevalence of the CPK increase

Outcome Description:

Dosage of CPK during standard blood sampling. The increase of CPK is defined when CPK value > USL

Outcome Time Frame:

Within 3 days after a clinical exam

Safety Issue:

No

Principal Investigator

Antoine ADENIS, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Centre Oscar Lambret

Authority:

France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé

Study ID:

TKI-CPK 1003

NCT ID:

NCT01248429

Start Date:

November 2010

Completion Date:

February 2011

Related Keywords:

  • Cancer
  • Solid Tumor
  • thyrosine kinase inhibitor
  • phosphokinase creatinin
  • myalgia
  • Neoplasms

Name

Location